Medications

Daratumumab cuts risk for progression in multiple myeloma

(HealthDay)—For patients with newly diagnosed multiple myeloma, the addition of daratumumab to lenalidomide and dexamethasone is associated with a reduced risk for disease progression or death, according to a study published ...

Medications

Stress hormones promote breast cancer metastasis

It has long been thought that stress contributes to cancer progression. Scientists from the University of Basel and the University Hospital of Basel have deciphered the molecular mechanisms linking breast cancer metastasis ...

Diseases, Conditions, Syndromes

Tuberculosis—Inhibiting host cell death with immunotherapy

Tuberculosis treatment still entails the administration of several antibiotics over a period of months and is torturous for many patients. The pathogen's increasing multidrug resistance additionally complicates this lengthy ...

Oncology & Cancer

Addition of elotuzumab ups PFS in refractory multiple myeloma

(HealthDay)—For patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor has failed, progression-free survival (PFS) is longer in those receiving the immunostimulatory monoclonal antibody ...

Diseases, Conditions, Syndromes

Study examines effectiveness of steroid medication for sore throat

In patients with a sore throat that didn't require immediate antibiotics, a single capsule of the corticosteroid dexamethasone didn't increase the likelihood of complete symptom resolution after 24 hours, and although more ...

Medications

Elotuzumab in multiple myeloma: Added benefit not proven

The monoclonal antibody elotuzumab has been approved in combination with lenalidomide and dexamethasone since May 2016 for further treatment of multiple myeloma in adults who have received at least one previous treatment. ...

page 5 from 8